The Secretary, acting through the Commissioner of Food and Drugs, may enter into collaborative agreements, to be known as Critical Path Public-Private Partnerships, with one or more eligible entities to implement the Critical Path Initiative of the Food and Drug Administration by developing innovative, collaborative projects in research, education, and outreach for the purpose of fostering medical product innovation, enabling the acceleration of medical product development, manufacturing, and translational therapeutics, and enhancing medical product safety.
In this section, the term "eligible entity" means an entity that meets each of the following:
The Secretary may not enter into a collaborative agreement under subsection (a) unless the eligible entity involved provides an assurance that the entity will not accept funding for a Critical Path Public-Private Partnership project from any organization that manufactures or distributes products regulated by the Food and Drug Administration unless the entity provides assurances in its agreement with the Food and Drug Administration that the results of the Critical Path Public-Private Partnership project will not be influenced by any source of funding.
Not later than 18 months after September 27, 2007, and annually thereafter, the Secretary, in collaboration with the parties to each Critical Path Public-Private Partnership, shall submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives-
In this section, the term "medical product" includes a drug, a biological product as defined in section 262 of title 42, a device, and any combination of such products.
To carry out this section, there is authorized to be appropriated $1,380,822 for the period beginning on October 1, 2022 and ending on December 23, 2022.1
1See 2022 Amendment notes below.
21 U.S.C. § 360bbb-5
EDITORIAL NOTES
AMENDMENTS2022-Subsec. (f). Pub. L. 117-328 which directed the substitution of "$6,000,000 for each of fiscal years 2023 through 2027" for "$1,265,753 for the period beginning on October 1, 2022 and ending on December 23, 2022", could not be executed because "$1,265,753" did not appear after the intervening amendment by section 301 of Pub. L. 117-229. See below. Pub. L. 117-229 substituted "$1,380,822 for the period beginning on October 1, 2022 and ending on December 23, 2022" for "$1,265,753 for the period beginning on October 1, 2022 and ending on December 16, 2022". Pub. L. 117-180 substituted "$1,265,753 for the period beginning on October 1, 2022 and ending on December 16, 2022" for "$6,000,000 for each of fiscal years 2018 through 2022".2017-Subsec. (f). Pub. L. 115-52 substituted "2018 through 2022" for "2013 through 2017". 2012-Subsec. (f). Pub. L. 112-144 amended subsec. (f) generally. Prior to amendment, text read as follows: "To carry out this section, there are authorized to be appropriated $5,000,000 for fiscal year 2008 and such sums as may be necessary for each of fiscal years 2009 through 2012."